Characterization of the latent membrane protein 1 signaling complex of Epstein-Barr virus in the membrane of mammalian cells with bimolecular fluorescence complementation

Virology Journal

David N Everly¹  Amanda Emery¹  Pooja Talaty¹ 

[1] Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Road, North Chicago, Illinois, 60064, USA

关键词: TRAF3;    TRAF2;    bimolecular fluorescence complementation;    latent membrane protein 1;    Epstein-Barr Virus;   

Others  :  1156221
DOI  :  10.1186/1743-422X-8-414

 received in 2011-05-16, accepted in 2011-08-24,  发布年份 2011

【 摘 要 】

Background

Bimolecular fluorescence complementation (BiFC) is a novel technique to examine protein-protein interaction through the assembly of fluorescent proteins. In the present study, BiFC was used to study the assembly of the Epstein-Barr virus latent membrane protein 1 (LMP1) signaling complex within the membrane of mammalian cells. LMP1 signaling requires oligomerization, localization to lipid rafts, and association of the cytoplasmic domain to adaptor proteins, such as the tumor necrosis factor receptor associated factors (TRAFs).

Methods

LMP1-TRAF and LMP1-LMP1 interactions were assayed by BiFC using fluorescence microscopy and flow cytometry. Function of LMP1 BiFC contructs were confirmed by transformation assays and nuclear factor- κB (NF-κB) reporter assays.

Results

BiFC was observed between LMP1 and TRAF2 or TRAF3 and mutation of the LMP1 signaling domains reduced complementation. Fluorescence was observed in previously described LMP1 signaling locations. Oligomerization of LMP1 with itself induced complementation and BiFC. LMP1-BiFC constructs were fully functional in rodent fibroblast transformation assays and activation of NF-κB reporter activity. The BiFC domain partially suppressed some LMP1 mutant phenotypes.

Conclusions

Together these data suggest that BiFC is a unique and novel platform to identify and characterize proteins recruited to the LMP1-signaling complex.

【 授权许可】

   
2011 Talaty et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Rickinson AB, Kieff E: Epstein-Barr Virus. In Fields Virology. Volume II. Fifth edition. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams and Wilkins; 2007::2655-2700.
• [2]Kieff ED, Rickinson AB: Epstein-Barr Virus and Its Replication. In Fields Virology. Volume II. 5th edition. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams and Wilkins; 2007::2603-2654.
• [3]Kaye KM, Izumi KM, Kieff E: Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993, 90:9150-9154.
• [4]Baichwal VR, Sugden B: Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 1988, 2:461-467.
• [5]Everly DN Jr, Mainou BA, Raab-Traub N: Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol 2004, 78:13470-13478.
• [6]Mainou BA, Everly DN Jr, Raab-Traub N: Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene 2005, 24:6917-6924.
• [7]Mainou BA, Everly DN Jr, Raab-Traub N: Unique signaling properties of CTAR1 in LMP1-mediated transformation. J Virol 2007, 81:9680-9692.
• [8]Moorthy RK, Thorley-Lawson DA: All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol 1993, 67:1638-1646.
• [9]Wang D, Liebowitz D, Kieff E: An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985, 43:831-840.
• [10]Raab-Traub N: Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002, 12:431-441.
• [11]Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, et al.: Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989, 321:1080-1085.
• [12]Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004, 4:757-768.
• [13]Dawson CW, Eliopoulos AG, Blake SM, Barker R, Young LS: Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells. Virology 2000, 272:204-217.
• [14]Eliopoulos AG, Young LS: Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 1998, 16:1731-1742.
• [15]Izumi KM, Kieff ED: The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 1997, 94:12592-12597.
• [16]Miller WE, Mosialos G, Kieff E, Raab-Traub N: Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol 1997, 71:586-594.
• [17]Paine E, Scheinman RI, Baldwin AS Jr, Raab-Traub N: Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins. J Virol 1995, 69:4572-4576.
• [18]Roberts ML, Cooper NR: Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 1998, 240:93-99.
• [19]Thornburg NJ, Kulwichit W, Edwards RH, Shair KH, Bendt KM, Raab-Traub N: LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice. Oncogene 2006, 25:288-297.
• [20]Ardila-Osorio H, Clausse B, Mishal Z, Wiels J, Tursz T, Busson P: Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Int J Cancer 1999, 81:645-649.
• [21]Ardila-Osorio H, Pioche-Durieu C, Puvion-Dutilleul F, Clausse B, Wiels J, Miller W, Raab-Traub N, Busson P: TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1. Int J Cancer 2005, 113:267-275.
• [22]Yasui T, Luftig M, Soni V, Kieff E: Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. Proc Natl Acad Sci USA 2004, 101:278-283.
• [23]Clausse B, Fizazi K, Walczak V, Tetaud C, Wiels J, Tursz T, Busson P: High concentration of the EBV latent membrane protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells. Virology 1997, 228:285-293.
• [24]Brown KD, Hostager BS, Bishop GA: Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 2001, 193:943-954.
• [25]Higuchi M, Izumi KM, Kieff E: Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc Natl Acad Sci USA 2001, 98:4675-4680.
• [26]Kaykas A, Worringer K, Sugden B: CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex. EMBO J 2001, 20:2641-2654.
• [27]Lee J, Sugden B: A membrane leucine heptad contributes to trafficking, signaling, and transformation by latent membrane protein 1. J Virol 2007, 81:9121-9130.
• [28]Kaykas A, Worringer K, Sugden B: LMP-1's transmembrane domains encode multiple functions required for LMP-1's efficient signaling. J Virol 2002, 76:11551-11560.
• [29]Soni V, Yasui T, Cahir-McFarland E, Kieff E: LMP1 transmembrane domain 1 and 2 (TM1-2) FWLY mediates intermolecular interactions with TM3-6 to activate NF-kappaB. J Virol 2006, 80:10787-10793.
• [30]Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G: Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 1996, 16:7098-7108.
• [31]Izumi KM, Cahir McFarland ED, Ting AT, Riley EA, Seed B, Kieff ED: The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol 1999, 19:5759-5767.
• [32]Huye LE, Ning S, Kelliher M, Pagano JS: Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol Cell Biol 2007, 27:2910-2918.
• [33]Ning S, Campos AD, Darnay BG, Bentz GL, Pagano JS: TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol Cell Biol 2008, 28:6536-6546.
• [34]Song YJ, Izumi KM, Shinners NP, Gewurz BE, Kieff E: IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3. Proc Natl Acad Sci USA 2008, 105:18448-18453.
• [35]Dawson CW, Laverick L, Morris MA, Tramoutanis G, Young LS: Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. J Virol 2008, 82:3654-3664.
• [36]Everly DN Jr, Mainou BA, Raab-Traub N: The ID proteins contribute to the growth of rodent fibroblasts during LMP1-mediated transformation. Virology 2008, 376:258-269.
• [37]Mainou BA, Raab-Traub N: LMP1 strain variants: biological and molecular properties. J Virol 2006, 80:6458-6468.
• [38]Everly DN Jr, Mainou BA, Raab-Traub N: Transcriptional downregulation of p27KIP1 through regulation of E2F function during LMP1-mediated transformation. J Virol 2009, 83:12671-12679.
• [39]Kung CP, Meckes DG Jr, Raab-Traub N: EBV Latent Membrane Protein 1 (LMP1) activates EGFR, STAT3 and ERK through effects on PKC{delta}. J Virol 2011.
• [40]Kung CP, Raab-Traub N: Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. J Virol 2008, 82:5486-5493.
• [41]Kung CP, Raab-Traub N: Epstein-Barr virus latent membrane protein 1 modulates distinctive NF- kappaB pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression. J Virol 2010, 84:6605-6614.
• [42]Thornburg NJ, Raab-Traub N: Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes. J Virol 2007, 81:12954-12961.
• [43]Piehler J: New methodologies for measuring protein interactions in vivo and in vitro. Curr Opin Struct Biol 2005, 15:4-14.
• [44]Kerppola TK: Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Nat Protoc 2006, 1:1278-1286.
• [45]Nyfeler B, Michnick SW, Hauri HP: Capturing protein interactions in the secretory pathway of living cells. Proc Natl Acad Sci USA 2005, 102:6350-6355.
• [46]Brennan P, Floettmann JE, Mehl A, Jones M, Rowe M: Mechanism of action of a novel latent membrane protein-1 dominant negative. J Biol Chem 2001, 276:1195-1203.
• [47]Floettmann JE, Rowe M: Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation. Oncogene 1997, 15:1851-1858.
• [48]Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995, 80:389-399.
• [49]Xia ZP, Sun L, Chen X, Pineda G, Jiang X, Adhikari A, Zeng W, Chen ZJ: Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009, 461:114-119.
• [50]Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK: The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009, 325:1134-1138.
• [51]Hennessy K, Fennewald S, Hummel M, Cole T, Kieff E: A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci USA 1984, 81:7207-7211.
• [52]Schultheiss U, Puschner S, Kremmer E, Mak TW, Engelmann H, Hammerschmidt W, Kieser A: TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J 2001, 20:5678-5691.
• [53]Remy I, Michnick SW: Regulation of apoptosis by the Ft1 protein, a new modulator of protein kinase B/Akt. Mol Cell Biol 2004, 24:1493-1504.
• [54]Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB: A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci USA 2006, 103:15014-15019.
• [55]Liu D, Songyang Z: ERM-mediated genetic screens in mammalian cells. Methods Enzymol 2008, 446:409-419.
• [56]Liu D, Yang X, Yang D, Songyang Z: Genetic screens in mammalian cells by enhanced retroviral mutagens. Oncogene 2000, 19:5964-5972.
• [57]Hiatt SM, Shyu YJ, Duren HM, Hu CD: Bimolecular fluorescence complementation (BiFC) analysis of protein interactions in Caenorhabditis elegans. Methods 2008, 45:185-191.
• [58]Shyu YJ, Suarez CD, Hu CD: Visualization of ternary complexes in living cells by using a BiFC-based FRET assay. Nat Protoc 2008, 3:1693-1702.
• [59]Shyu YJ, Suarez CD, Hu CD: Visualization of AP-1 NF-kappaB ternary complexes in living cells by using a BiFC-based FRET. Proc Natl Acad Sci USA 2008, 105:151-156.